Creating Compound Screening Libraries That Address the Challenges of Drug Discovery, New Webinar Hosted by Xtalks
Toronto, ON, June 8, 2018 (Newswire.com) - The identification of high-quality, innovative small molecule lead compounds remains a challenge in drug discovery. Access to innovative compound libraries is crucial in order to address the challenges associated with discovering new drugs. The chemical space to be sampled in drug discovery programs is vast and sparsely populated by existing compound collections. Therefore, significant efforts and resources need to be invested in the generation and maintenance of competitive compound collections for biological screening.
In this live webinar, Michael P. Trova, PhD, Senior Vice President of Drug Discovery at AMRI will present the characteristics of a high-quality compound screening collection. AMRI’s approach to synthesizing compound screening collections is addressing this challenge by leveraging its synthetic and medicinal chemistry expertise.
This webinar on Tuesday, June 19, 2018, at 11am EDT (4pm BST/UK), will discuss AMRI’s cost-effective approach to the creation of high-value screening compounds.
For more information about this complimentary webinar visit: Creating Compound Screening Libraries That Address the Challenges of Drug Discovery.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical and biotech companies, private and academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/sponsorship.ashx
Tel: +1 (416) 977-6555 ext 352
Categories: Pharmaceuticals and Biotech